Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria

Karan Uppal, Emory University
Jorge Salinas, Emory University
Wuelton M. Monteiro, Universidade do Estado do Amazonas
Fernando Val, Universidade do Estado do Amazonas
Regina Cordy, Emory University
Ken Liu, Emory University
Gisely C. Melo, Universidade do Estado do Amazonas
Andre M. Siqueira, Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ)
Belisa Magalhaes, Universidade do Estado do Amazonas
Mary Galinski, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: PLoS ONE
Volume: Volume 12, Number 8
Publisher: Public Library of Science | 2017-08-16, Pages e0182819-e0182819
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pone.0182819
Permanent URL: https://pid.emory.edu/ark:/25593/s4sbt

Final published version: http://dx.doi.org/10.1371/journal.pone.0182819

Copyright information:

© 2017 Uppal et al
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed March 10, 2022 12:06 PM EST
Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in *Plasmodium vivax* malaria

Karan Uppal1,2*, Jorge L. Salinas2,3,4, Wuelton M. Monteiro5,6, Fernando Val5,6, Regina J. Cordy2,3, Ken Liu1, Gisely C. Melo5,6, Andre M. Siqueira7, Belisa Magalhaes5, Mary R. Galinski2,3,4, Marcus V. G. Lacerda5,8*, Dean P. Jones1,2

1 Clinical Biomarkers Laboratory, Division of Pulmonary Medicine, Department of Medicine, Emory University, Atlanta, Georgia, United States of America, 2 Malaria Host–Pathogen Interaction Center, Atlanta, Georgia, United States of America, 3 International Center for Malaria Research, Education and Development, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, Georgia, United States of America, 4 Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America, 5 Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil, 6 Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil, 7 Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil, 8 Instituto Leônidas & Maria Deane (FIOCRUZ), Manaus, Amazonas, Brazil

*marcuslacerda.br@gmail.com; kuppal2@emory.edu

Abstract

Background

Chloroquine (CQ) is the main anti-schizontocidal drug used in the treatment of uncomplicated malaria caused by *Plasmodium vivax*. Chloroquine resistant *P. vivax* (PvCR) malaria in the Western Pacific region, Asia and in the Americas indicates a need for biomarkers of resistance to improve therapy and enhance understanding of the mechanisms associated with PvCR. In this study, we compared plasma metabolic profiles of *P. vivax* malaria patients with PvCR and chloroquine sensitive parasites before treatment to identify potential molecular markers of chloroquine resistance.

Methods

An untargeted high-resolution metabolomics analysis was performed on plasma samples collected in a malaria clinic in Manaus, Brazil. Male and female patients with *Plasmodium vivax* were included (n = 46); samples were collected before CQ treatment and followed for 28 days to determine PvCR, defined as the recurrence of parasitemia with detectable plasma concentrations of CQ ≥100 ng/dL. Differentially expressed metabolic features between CQ-Resistant (CQ-R) and CQ-Sensitive (CQ-S) patients were identified using partial least squares discriminant analysis and linear regression after adjusting for covariates.
and multiple testing correction. Pathway enrichment analysis was performed using Mummichog.

**Results**

Linear regression and PLS-DA methods yielded 69 discriminatory features between CQ-R and CQ-S groups, with 10-fold cross-validation classification accuracy of 89.6% using a SVM classifier. Pathway enrichment analysis showed significant enrichment \( p < 0.05 \) of glycerophospholipid metabolism, glycosphingolipid metabolism, aspartate and asparagine metabolism, purine and pyrimidine metabolism, and xenobiotics metabolism. Glycerophosphocholines levels were significantly lower in the CQ-R group as compared to CQ-S patients and also to independent control samples.

**Conclusions**

The results show differences in lipid, amino acids, and nucleotide metabolism pathways in the plasma of CQ-R versus CQ-S patients prior to antimalarial treatment. Metabolomics phenotyping of *P. vivax* samples from patients with well-defined clinical CQ-resistance is promising for the development of new tools to understand the biological process and to identify potential biomarkers of PvCR.

**Introduction**

Malaria is a global health infectious disease problem with almost half of the world's population at risk. Among the *Plasmodium* species causing malaria, *P. vivax* is the leading cause of malaria in extensive areas of the world [1], with more than 8.5 million cases estimated in 2015 [2]. Most common manifestations of severe vivax malaria include severe anemia and respiratory distress, and these are particularly associated with young age [3–5]. The decline in malaria in the Americas since the 1990’s continues to fuel hope for its eventual elimination [6]. However, emerging resistance to antimalarial treatment poses a threat to such efforts. Chloroquine (CQ) is the main drug used in the treatment of uncomplicated vivax malaria. CQ accumulates in the digestive vacuole, an acidic compartment, of the parasite [7]. The high intravacuolar concentration of CQ is proposed to inhibit heme biocrystallization, thus leading to heme build up in toxic levels and inhibition of various processes in the parasite cell [8, 9]. Various proteins and lipids have been implicated in pigment biocrystallization, but their precise role and the effect of drugs in the process remains to be elucidated [10]. Furthermore, CQ is active only against the blood stages of the malaria parasite (namely trophozoites and schizonts), in which the parasite is actively degrading hemoglobin, but it is not active against infectious sporozoites, liver-stage schizonts and hypnozoites [8, 11]. Previous studies have shown the association of membrane proteins, which are involved in transport of drugs, lipids, and peptides with drug resistance [12–14].

There have been many reports on CQ-resistance from different regions of the world [15–19] including Brazil [20–23]. The widespread emergence and spread of CQ-resistance in *P. vivax* (PvCR) represent one of the greatest threats to control and elimination efforts [24]. Moreover, molecular mechanisms of CQ-resistance in *P. vivax* are poorly understood and currently there is no validated biomarker for this parasite phenotype, preventing reliable drug resistance surveillance in endemic regions [25].
In the western Brazilian Amazon, in an analysis of 135 individuals, a higher initial mean parasitemia was associated with CQ-resistance in *P. vivax* (PvCR) in 5.2% of the patients at day 28. Hemoglobin levels were similar at the beginning of the follow-up period but were significantly lower at days 3 and 7 post-treatment in the patients with resistant infections [22]. Parasites from patients with PvCR presented up to 6.1 and 2.4 fold increase in *pvcrt-o* and *pvmdr-1* expression levels, respectively, compared to the susceptible group [26]. In *vivo* overexpression of both genes, irrespective of the absence of mutations in *P. vivax* genes for transporters and folate pathway *P. falciparum* ortholog genes linked to CQ-resistance [22, 26], indicates that components of epigenetic regulation may be involved in the PvCR phenomenon, including the effects of nutritional, metabolic and immune factors, as suggested from longitudinal drug resistance studies in complicated and non-complicated malaria [26, 27]. Several studies based on *P. vivax* isolates from Southeast Asia have shown the involvement of copy number variation of *pvcrt* or *pvmdr* genes with the CQ-resistant phenotype [28, 29]. In the Brazilian Amazon, copy number amplification of these genes is expected to be very low among *P. vivax* strains (0.9%) [30] and below the estimates of CQ-resistance in this area [21]. This suggests an alternative mechanism for CQ-resistance instead copy number amplification.

Metabolomics in malaria, namely targeted metabolomics, was applied almost exclusively to identify *P. falciparum* stage-specific changes in metabolic pathways involved in parasite differentiation and invasion in order to better inform drug discovery and design [31–35] or to predict disease severity [36–39]. In this context, metabolomics has been used to gain understanding of the intraerythrocytic development cycle of *P. falciparum* in cell culture studies, expanding the knowledge of amino acid and lipid metabolism [40, 41]. Application of untargeted high-resolution metabolomics (HRM) [42] using liquid chromatography coupled to ultra-HRM spectrometry was used with advanced data extraction algorithms [43, 44] and a metabolome-wide association study (MWAS) to identify metabolites associated with *P. falciparum* infection in *in vitro* culture samples [45]. The study of the *P. falciparum* intraerythrocytic development cycle revealed increased 3-methylindole, a mosquito attractant; succinylacetone, a heme biosynthesis inhibitor; S-methyl-L-thiocitrulline, a nitric oxide synthase inhibitor; and O-arachidonoyl glycidol, a fatty acid amide hydrolase inhibitor [45]. Each of these could be mechanistically important in the parasite’s life cycle and disease manifestations. Coupled with the mechanistic data for metabolic pathways involved in parasite differentiation and invasion, metabolomics results highlight an important need and opportunity to apply HRM for studies of drugs on parasite metabolism and resistance to antimalarials.

Metabolomics remains a relatively new field for malaria research and insights are currently lacking on the metabolic changes that occur during *P. vivax* development. In the present study, we examined plasma metabolomics of samples obtained before CQ treatment from patients infected with *P. vivax* who were subsequently classified as CQ-R and CQ sensitive (CQ-S) after a 28-day follow-up period in the Brazilian Amazon. A metabolome-wide association study (MWAS) was performed to determine differentially expressed metabolites and perturbed metabolic pathways between CQ-R and CQ-S patients. Results could facilitate development of optimal treatment therapies and clinical diagnostic tests for tracking and therapeutically targeting such processes [46].

**Methods**

Patients with vivax malaria were enrolled in this study from June 2011 to December 2012 at the *Fundação de Medicina Tropical Doutor Heitor Vieira Dourado* (FMT-HVD), an infectious disease referral center located in Manaus, Western Brazilian Amazon. This study, which required a 42-day follow-up period, was approved by the FMT-HVD Institutional Review Board.
Board and the Brazilian National Ethics Committee (CONEP) (IRB approval #: CAAE: 12516713.8.0000.0005). All protocols and documentation were reviewed and sample shipments approved by the Emory IRB. A written informed consent was obtained from study participants. In case of children/minors, a written informed consent was obtained from parents and legal guardians on behalf of their participants. A schematic of the study design is shown in Fig 1. Male and female patients were eligible for inclusion if aged 6 months to 60 years, body-weight \( \geq 5 \) kg, presenting a blood parasite density from 250 to 100,000 parasites/microliter and axillary temperature \( \geq 37.5 \)^\circ C or history of fever in the last 48 hours. Exclusion criteria were: use of antimalarials in the previous 30 days, refusal to be followed up for 42 days and any clinical complication. Patients received supervised treatment with 25 mg/kg of CQ phosphate over a 3-day period (10 mg/kg on day 0 and 7.5 mg/kg on days 1 and 2) according to the guidelines of the Brazilian Ministry of Health. Primaquine (0.5 mg/kg per day for 7 days) was prescribed at the end of the 42-day follow-up period [47]. Patients who vomited the first dose within 30 minutes after drug ingestion were re-treated with the same dose. Patients were evaluated on days 0, 1, 2, 3, 7, 14, 28 and 42 and, if they felt ill, at any time during the study period. Blood smear readings, complete blood counts, and diagnostic polymerase chain reaction (PCR) amplifications were performed at all time points. Three aliquots of 100 \( \mu L \) of whole blood from the day of a recurrence were spotted onto filter paper for later analysis by high performance liquid chromatography (HPLC) to estimate the levels of CQ and desethylchloroquine (DCQ) as previously described [19]. In this study, CQ-resistance with parasitological failure was defined as parasite recurrence in the presence of plasma concentrations of CQ and DSQ higher than 100 ng/mL and microsatellite analysis revealing the presence of the same clonal nature at diagnosis and recurrence [26]. The CQ-sensitive control group consisted of patients with no parasitemia recurring during follow-up period. A group of 20 healthy individuals from Brazil

---

https://doi.org/10.1371/journal.pone.0182819.g001
was used as non-malarial control group. All samples were processed after blood collection and immediately the plasma was separated and further stored at -80°C until metabolomics.

**Plasmodium vivax** malaria diagnosis

Thick blood smears were prepared as recommended by the Walker technique and evaluated by an experienced microscopist [48]. Parasite densities (parasites/μL) were calculated by counting the number of parasites per 500 leukocytes in high magnification fields, and the number of leukocytes/μL per patient. In addition, differential counting of asexual forms (ring-stage parasites, mature trophozoites and schizonts) was performed to ensure that there was no difference between groups of cases and controls. Afterwards, real-time PCR was performed to confirm *P. vivax* mono-infection. The extraction of total DNA from whole blood was performed using the QIAamp DNA Blood Mini Kit (Qiagen, USA), according to the manufacturer’s protocol. The DNA was amplified in an Applied Biosystems 7500 Fast System using primers and TaqMan fluorescence labeled probes for real time PCR [49].

**High-resolution metabolomics**

The composition of the metabolites present in plasma samples was determined using liquid chromatography-HRM spectrometry (LCMS, Accela- LTQ Velos Orbitrap; mass-to-charge, m/z, range from 85–2000, positive electrospray ionization). Aliquots of 200 μL of plasma were treated with acetonitrile (2:1) with 14 stable isotope internal standards ([13C6]-D-glucose, [15N]-indole, [2,15N]-L-lysine dihydrochloride, [13C5]-L-glutamic acid, [3,4,13C2]-cholesterol, [15N]-L-tyrosine, [trimethyl-13C]-caffeine, [15N2]-uracil, [3,3,13C2]-cystine, [1,2,13C2]-palmitic acid, [15N,13C3]-L-methionine, [15N]-choline chloride, and 2'-deoxyguanosine-[15N2,13C10]-5'-monophosphate), centrifuged to remove protein, and analyzed in triplicate with a 10 μL injection volume on a C18 reverse phase column with a formic acid/acetonitrile gradient [50]. Several nutrition and health assessment studies and cross-laboratory comparisons have shown that the C18 chromatography can be used for quantification of several endogenous and exogenous metabolites involved in the amino acids metabolism, fatty acid metabolism, nucleotide metabolism, vitamin coenzymes, and environmental chemicals [51, 52]. Although the methods use ultra-high resolution mass spectrometry, the 10-minute gradient used in this study cannot resolve structural isomers and isobaric species [44]. Peak detection, noise removal, and alignment was performed using apLCMS v6.0.1[53] and xcms v1.44[54] with xMSanalyzer v2.0.4[43], yielding a data table with accurate mass (m/z), retention time and intensity for each m/z feature across all samples. An m/z feature is defined as the unique combination of m/z, retention time, and intensity profile. Batch-effect correction was performed using ComBat [55].

**Bioinformatics and statistics**

Descriptive statistics were employed to evaluate patient characteristics to ensure distributional assumptions for statistical tests were met. A bivariate analysis was performed to identify variables associated with CQ-R using t-test or Wilcoxon Rank-Sum test for continuous variables and Chi-square test for categorical variables. Metabolomics data were filtered to remove features not present in at least 80% of one group or >50% of all samples. After filtering, missing values were imputed by one-half of the lowest signal detected for that feature across all samples [56]. Data were then log2 transformed and quantile normalized [57, 58]. Both univariate and multivariate methods were used to identify differentially expressed m/z features between CQ-R and CQ-S groups. For univariate analysis, a multiple linear regression model with log2 transformed intensities of m/z features as dependent variable and response to CQ treatment
(CQ-R versus CQ-S) and potential confounding factors (platelet count, age, and gender) as independent variables was fitted for each \( m/z \) feature. Multiple hypothesis correction was performed using the Benjamini-Hochberg false discovery rate (FDR) correction method [59]. Type 1 (-log\(_{10}\) \( p \) vs \( m/z \)) and Type 2 (-log\(_{10}\) \( p \) vs retention time) Manhattan plots were used to visualize the pattern of differential expression across all features with respect to molecular mass and chemical properties, respectively. Multivariate analysis was performed using partial least squares discriminant analysis (PLS-DA) implemented in the R package mixOmics v5.2.0, and discriminatory features were selected using the variable importance for projection (VIP > 1.5) measure [60]. Fold change of raw intensity values was calculated for each feature as a ratio of average intensity from CQ-R and CQ-S groups. A consensus feature selection framework was used such that only features selected by both univariate and multivariate methods with a fold change greater than two between CQ-R and CQ-S groups were considered as discriminatory features. Two-way hierarchical clustering analysis (HCA) was performed to visualize the relationship between subjects and discriminatory features between CQ-R and CQ-S groups. The classification accuracy of discriminatory features and clinical variables was evaluated using a support vector machine (SVM) classifier and a 10-fold cross-validation procedure, which was repeated ten times. Permutation testing was performed by randomly shuffling the class labels of the subjects. The abundance level of top discriminatory metabolites in subjects with CQ-R and CQ-S parasites was compared to 20 controls from Brazil, pooled plasma from 20 healthy individuals from the United States, and National Institute of Standards and Technology (NIST) pooled Standard Reference Material SRM1950 [61]. 95% confidence intervals were used to represent the metabolite levels for controls, CQ-R, and CQ-S groups.

### Metabolite annotation, pathway analysis, and MS/MS

Annotation of discriminatory features was performed using xMSannotator v1.2 with the Human Metabolome Database (HMDB v3.6) [62]. xMSannotator uses adduct/isotope patterns, correlation in intensities across all samples, retention time difference between adducts/isotopes of a metabolite, and network and pathway associations for associating \( m/z \) features with known metabolites and categorizing database matches into different confidence levels. This multi-step annotation process reduces the number of false matches as compared to only \( m/z \) based database search [62]. Mummichog v0.10.3 was used to perform pathway enrichment analysis using \( m/z \) features that were significant at \( p < 0.05 \) and had VIP > 1 [63]. Although the annotation step in mummichog at the individual metabolite level includes false matches, the software uses statistical tests to compare the enrichment pattern of the real metabolite subsets with null distribution, thereby allowing prioritization of pathways for further evaluation [44]. MS/MS analysis of the top discriminatory features with high confidence matches in xMSannotator was performed on a Dionex UHPLC system using C18 chromatography (Higgins Analytical) coupled to a Thermo Fisher Orbitrap Fusion mass spectrometer (HCD—35 eV, 1 AMU isolation window, 120,000 resolution). Raw MS/MS data was processed using DeconMSn [64] and the experimental spectra were compared to MS/MS spectra in Metlin and mzCloud [65, 66].

### Results

Forty-six patients were included in all analyses, 15 CQ-R and 31 CQ-S. The mean age was 33 ± 16.4 years and 10 were female (Table 1). The median hemoglobin at the time of enrollment was 13.75 g/dl (IQR 12.4–14.28 g/dl). The median parasitemia at the time of enrollment was 1.9x10\(^3\) parasites/\( \mu \)l (IQR 0.8–3.3 x10\(^3\) parasites/\( \mu \)l). Bivariate analyses were performed to find
variables associated with the study outcome and platelet count levels at the time of enrollment were found to be associated with CQ resistance ($p<0.05$, Table 1).

To determine whether metabolic differences occurred between patients subsequently classified as CQ-R and CQ-S, HRM was performed on associated samples collected prior to initiation of CQ treatment (Metabolomics Workbench ID: ST000578). High-resolution metabolomics provided data for 21,360 $m/z$ features; after filtering for missing values, 3,049 $m/z$ features were log$_2$ transformed and quantile normalized for downstream statistical analyses using a consensus feature selection framework (S1 Table). Using the univariate approach, 81 $m/z$ features were selected as discriminatory features between CQ-R and CQ-S groups at FDR $<0.20$ (Fig 2A and 2B). The green (higher in CQ-R) and red (lower in CQ-R) circles above the dotted horizontal line (FDR 0.2 threshold) represent the discriminatory features. The type 1 Manhattan plot shows discriminatory features with a broad range of $m/z$, -log$_{10}$ $P$ versus $m/z$ (Fig 2A). 77% of the discriminatory features had retention time greater than 4 minutes (Fig 2B). This is consistent with the elution pattern of lipids using reverse-phase chromatography [67]. The less stringent FDR cutoff could facilitate identification of biologically meaningful associations [68]. As an alternative approach, discriminatory features were selected using the Variable Importance for Projection (VIP) scores in a PLS-DA model, which is a multivariate method. Sixty nine of the 81 discriminatory features selected using the univariate approach were also selected at a VIP threshold of 1.5 and had greater than 2-fold increase or decrease in abundance levels between the CQ-R and CQ-S groups (S1 and S2 Tables). Less than 12% of the discriminatory features were associated with the potential confounders ($p<0.05$) in the linear regression model (S2 Table).

Two-way hierarchical clustering analysis (HCA) was performed using the discriminatory features to identify clusters of samples and $m/z$ features. Hierarchical clustering analysis showed that the discriminatory features grouped into 14 clusters that could be combined into two major clusters comprised of features with differential expression patterns (up-regulated or down-regulated) between the two groups (Fig 2C). Pathway enrichment analysis using Mum-michog showed significant enrichment ($p<0.05$) of several pathways related to lipid and amino acids metabolism: glycerophospholipid metabolism, glycosphingolipid metabolism,
aspartate and asparagine metabolism, purine and pyrimidine metabolism, and xenobiotics metabolism (Fig 2D and S3 Table).

Annotation of the top discriminatory features using xMSannotator followed by MS/MS evaluation showed that a subset of features was glycerophosphocholines (S1 Fig and S2 Table). The acquired MS/MS spectra for m/z 510.3535 (S1A Fig) matched the spectra for LysoPC (17:0) (level 2 confidence level based on Schymanski et al. [69]) in Metlin. The MS/MS included diagnostic fragments m/z 184.0734 (phosphocholine) and m/z 104.1071 (choline) for LysoPCs [70]. The MS/MS spectra for m/z 516.3058 annotated as M+Na form of LysoPC (16:1) using xMSannotator had one diagnostic fragment, m/z 104.1071 (choline) consistent with glycerophosphocholines (S1B Fig; level 2 confidence level based on Schymanski et al. [69]). However, xMSannotator assigned multiple co-eluting and correlated features to different forms (M+H, M+Na, and 13C M+H) of LysoPC(16:1). Additionally, we have previously shown that this feature is significantly correlated with choline and other forms of this metabolite [71].

As an alternative data extraction approach, the data were also processed using XCMS [54]. The glycerophosphocholines were significantly different between CQ-R and CQ-S subjects at p<0.05 and had VIP>2 using PLS-DA (S2A Fig). Additionally, pathway analysis based on xcms results also showed enrichment of glycerophospholipid metabolism (S2B Fig), thereby indicating that association of glycerophosphocholines with CQ-R is likely to be a real biological phenomenon and not an analytical artifact.

The abundance levels of the glycerophosphocholines were significantly lower in the CQ-R group as compared to CQ-S subjects and also to independent control samples NIST SRM1950 pooled plasma samples, plasma samples from 20 healthy controls from Brazil, and plasma samples from 20 controls from the US, with p<0.05 regarded as significant (Fig 3).

Comparisons of 10-fold cross-validation accuracy using only platelet counts, only glycerophosphocholines, top 10 and top 30 discriminatory features ranked based on VIP, and using
all 69 discriminatory metabolic features show that the metabolic features allow up to 89.6% 10-fold classification accuracy as compared to 65% using only the platelet counts (Fig 4). Both clinical variables and metabolic features performed better than the randomly generated models.

Fig 3. Comparison of glycerophosphocholine abundance levels in NIST, pooled normal plasma (US), healthy controls (Brazil), CQ-Resistant (*P. vivax*), and CQ-Sensitive (*P. vivax*) groups along with 95% confidence intervals. The glycerophosphocholines were found to be lower in CQ-Resistant group as compared to CQ-Sensitive and other control samples (*p<0.05*).

https://doi.org/10.1371/journal.pone.0182819.g003

Fig 4. 10-fold cross-validation analysis using clinical variables and top discriminatory metabolic features. 10-fold cross-validation classification accuracies varied from 65% to 89.6% using platelet count, glycerophosphocholines, top 10, top 30, and all 69 discriminatory features. The average permuted accuracies (N = 1000 permutations) varied from 55–58%.

https://doi.org/10.1371/journal.pone.0182819.g004
Discussion

Here, by comparing the plasma metabolic profiles before CQ treatment of individuals with *P. vivax* infections in Brazil, we have identified metabolic signatures that could allow prediction of PvCR. Previous studies did not find any associations between clinical response to CQ and polymorphisms in the *pvcrt-o, pvmdr1, pvdhfr, pvmrp1*, and *pvdhps* genes in *P. vivax* subjects [22, 26, 28, 72–75]. The correlation between *ex vivo* CQ resistance and sequence polymorphisms in PvCR candidate genes is limited and contradictory [15, 76]. In terms of gene transcription, however, parasites from patients with PvCR presented up to 6.1 and 2.4 fold increase in *pvcrt-o* and *pvmdr-1* transcription levels, respectively, compared to the susceptible group [26]. Caution is needed when attempting to extrapolate the *ex vivo* biomarkers of resistance to the clinical response, since *pvcrt-o* transcription was not a primary determinant of *ex vivo* drug susceptibility [77]. These previous observations suggest that host-parasite interaction factors, such as nutritional and immune components and clinical severity grading, rather than parasite constitutional factors *per se*, may be involved in PvCR [26, 27, 78]. In this context, coordinated use of metabolic phenotyping of samples from *P. vivax* patients presenting with well-defined clinical resistance to CQ holds much promise for the development of new tools to understand the biological process of PvCR and to identify potential biomarkers of PvCR.

Chloroquine mechanism(s) of action has been an intense area of research for decades. Evidence supports that the principal target is the heme detoxification pathway in the digestive vacuole, where the parasite degrades erythrocytic hemoglobin and polymerizes the liberated toxic heme monomers to inert biocrystals of hemozoin [8, 9]. Inhibition of heme polymerization would lead to a toxic milieu to the parasite with its own excreta. Thus, *Plasmodium* with a low hemozoin production phenotype should present as CQ-R [79] as observed for *P. falciparum* [80]. Catabolism of host hemoglobin in *Plasmodium berghei*-infected reticulocytes is also down regulated in CQ-resistant parasites [81]. Interestingly, replication of *Plasmodium* developing inside reticulocytes, such as *P. vivax*, can occur without hemozoin formation, resulting also in CQ-resistance [82]. In the current study, lipid (glycerophospholipid and glycosphingolipid metabolism) and amino acids (aspartate and asparagine metabolism) pathways were dissimilarly expressed in PvCR carriers. Lipid membranes and proteins are typically involved in biomineralization processes in *Plasmodium* [83–87], suggesting a modulation in terms of quantitative expression of these groups of metabolites in *P. vivax* with different degrees of CQ sensitivity.

Here, glycerophospholipids and glycosphingolipids metabolism pathways were differentially expressed in CQ-R and CQ-S subjects before treatment. Glycerophospholipids are the main *Plasmodium* membrane constituents, with the predominant phosphatidylcholine and phosphatidylethanolamine lipids originating from the parasite-encoded enzymatic machinery for membrane neogenesis, which requires high amounts of phospholipids [88]. Previous studies have shown alterations in phospholipase A2 (PLA2) activity, which is involved in the glycerophospholipid metabolism, during *P. vivax* malaria in human studies and in erythrocytes infected with *P. falciparum* following CQ treatment [89]. Chloroquine has high affinity for membrane phospholipids, and inhibition of *Plasmodium* PLA2 may be important for therapeutic action [89, 90]. Furthermore, previous studies have shown the involvement of transporter genes and membrane proteins that involved in the transport of drugs and lipids with antimalarial drug resistance [14]. Glycosphingolipids are important components of cellular membranes involved in various biological functions, and their biosynthesis was described in *Plasmodium* by an active malarial glucosylceramide synthase [91, 92]. Marked lower levels of glycerophosphocholines in CQ-R compared to CQ-S and control groups and perturbation of the glycerophospholipid metabolism based on the pathway analysis indicates that there could be perturbed PLA2 activity in the CQ-R subjects before treatment. Alternatively, CQ-R parasites
may have the ability to utilize the host glycerophosphocholines, and therefore be able to survive even when CQ inhibits the \textit{Plasmodium} PLA2. There is a well-documented link between hemozoin formation and lipid membrane metabolism \cite{93-96}. Considering that host hemoglobin catabolism and hemozoin production are reduced in CQ-R infected cells \cite{79}, a differential expression in glycerophospholipids, glycosphingolipids and glycerophosphocholines pathways are expected from parasites, with further decreased levels of their metabolites. Since glycerophosphocholines levels were decreased in mice presenting severe malaria, especially cerebral malaria \cite{97, 98}, one also speculates that parasite virulence or host-parasite interactions may be different in CQ-R and CQ-S phenotypes. In addition, a slower hemoglobin digestion process in patients with CQ-R infected cells may result in a milder inflammatory profile and in a reduced cell turnover of those metabolites compared to CQ-S carriers \cite{99, 100}.

In addition to pathways related to lipid metabolism, metabolomics also suggests perturbations in aspartate and asparagine metabolism and nucleotide metabolism. \textit{Plasmodium} has a rudimentary pathway for amino acid biosynthesis, depending mainly on host hemoglobin degradation and extracellular sources to meet its amino acid requirements \cite{101}. Of these amino acids, asparagine plays a pivotal role in the parasite life cycle by serving as one of the most abundant amino acids in \textit{P. vivax} \cite{102}. Consequently, malaria parasites have retained asparagine synthetase, which catalyzes the formation of asparagine from aspartate \cite{101}. In situations of high parasite load or low-hemozoin producer phenotypes, in which arginine requirements are expected to be higher \cite{103}, depletion of blood asparagine levels and increased transcription of parasite asparagine synthetase may occur \cite{104}. \textit{Plasmodium} parasites are unable to synthesize purines \textit{de novo} and have to salvage them from the host through endogenous host erythrocyte transporters \cite{105}. As observed for amino acids, dissimilar requirements of nucleotide by CQ-R and CQ-S phenotypes may explain the higher uptake of purines from the host, which is consistent with our results. Moreover, purine and pyrimidine metabolism pathways have previously been associated with inflammation and enhanced immune cell turnovers \cite{106}. Accordingly, circulating nucleic acids increase in patients with \textit{P. vivax} \cite{107}, pointing to the involvement of host response leading to differences in nucleotide pathways between groups. Interestingly, metabolomics demonstrates that \textit{Plasmodium} can utilize elements of the reserves of reticulocytes, namely nucleotides, which are absent in mature red blood cells \cite{108}. Phenotype-specific differences in reticulocyte stages tropism or dissimilar trends in differentiation in reticulocyte resident parasites may result in notable differences in the necessity for parasite intrinsic metabolism. The xenobiotic metabolism pathway included two hydroxynaphthalene metabolites (common air pollutants) \cite{109} dependent upon cytochrome P450 activities. Since CQ metabolism is also associated with cytochrome P450 \cite{110}, naphthalene and other environmental chemicals could influence this result.

One of the limitations of the current study is the small number of human plasma samples available for comparison. Although a consensus feature selection framework was used with both univariate and multivariate methods to reduce the risk of over-fitting, additional validation studies will be required to replicate these findings in independent cohorts. Further, the host inflammatory state was not extensively explored in this study, and may also influence the results, as plasma metabolic changes are observed during immune responses \cite{111}. More detailed investigations exploring the host immune response alongside the parasite will enable a clearer understanding of the respective roles of host and parasite in the altered metabolic state of the CQ-R individuals. Future work will focus on validating these findings in an independent set of samples, including samples from different endemic regions. Additionally, future investigations will focus on improving our understanding of the CQ-host-vivax relationship.

Host nutritional status may influence malaria susceptibility and host and parasite metabolomics, but the direct effect of a subject’s nutritional status was not assessed in this work when...
adjusting the analysis. Indeed, evidence of an exacerbating role of malnutrition on malaria can be seen in longitudinal drug resistance studies. A slower parasite clearance, higher parasitemia at presentation and more severe drug resistance were seen in malnourished Rwandan refugees [112]. Likewise, in the Solomon Islands [113, 114] and Malawi [115] malnourished children were significantly more prone to experience treatment failures than those better nourished. These findings emphasize the complex metabolic pathways through which nutrients may influence malaria parasites and host morbidity and bring new insights to explore the previous associations between CQ-resistance and malaria severity [22, 26] using high-resolution metabolomics to integrate nutrition to host and parasite metabolism in the future.

**Conclusion**

We present the first report of the use of high-resolution metabolomics to identify metabolites and metabolic pathways related to PvCR. The results show differences in glycerophospholipid and glycosphingolipid metabolism, aspartate and asparagine metabolism, and purine and pyrimidine metabolism pathways in CQ-R vs CQ-S subjects prior to antimalarial treatment. Based on previous studies, low catabolism of host hemoglobin with further lower hemozoin formation in *P. vivax*-infected reticulocytes in CQ-resistant parasites could be involved in this sequence of metabolic alteration. Although the number of samples in this study was small, the results demonstrate the future potential of HRM in identifying *P. vivax* infected individuals that are likely to show CR, and thus facilitate the design of optimal treatment plans. We present differentially expressed metabolites and perturbed pathways that will require further validation in clinical human cohorts and animal studies. Components of host metabolism regulation may be involved in the PvCR phenomenon, including the effects of nutritional, metabolic and immune factors.

**Supporting information**

S1 Table. Data table for 3,049 m/z features along with metadata and statistical evaluation results. (XLSX)

S2 Table. Statistical evaluation and annotation results of 69 discriminatory features. (XLSX)

S3 Table. Data for metabolites involved in perturbed pathways shown in Fig 1D. (XLSX)

S1 Fig. MS/MS evaluation of m/z features matching LysoPCs, A) Comparison of experimental MS/MS spectra for m/z 510.3535 annotated as LysoPC (17:0) with reference spectra in Metlin; B) MS/MS fragments for m/z 516.3058 annotated as LysoPC(16:1). (TIF)

S2 Fig. Summary of statistical and pathway analysis results based on feature table generated using XCMS. A) Box plots of LysoPC (17:0) and LysoPC(16:1) with p<0.05 and VIP>2; B) Pathway analysis results of significant features showed enrichment of glycerophospholipid metabolism pathway. (TIF)

**Acknowledgments**

We are grateful to the patients and clinical staff at the FMT-HVD and all members of the MaHPIC Consortium, particularly Esmeralda VS Meyer for supportive managerial aspects of this collaboration.
Author Contributions

Conceptualization: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Data curation: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Ken Liu, Gisely C. Melo, Andre M. Siqueira, Belisa Magalhaes, Marcus V. G. Lacerda.

Formal analysis: Karan Uppal, Jorge L. Salinas, Ken Liu.

Funding acquisition: Jorge L. Salinas, Wuelton M. Monteiro, Fernando Val, Mary R. Galinski, Marcus V. G. Lacerda.

Investigation: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Ken Liu, Gisely C. Melo, Andre M. Siqueira, Belisa Magalhaes, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Methodology: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Marcus V. G. Lacerda, Dean P. Jones.

Project administration: Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Resources: Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Software: Karan Uppal.

Supervision: Wuelton M. Monteiro, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Validation: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Regina J. Cordy, Ken Liu.

Visualization: Karan Uppal, Jorge L. Salinas, Ken Liu.

Writing – original draft: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Ken Liu, Gisely C. Melo, Andre M. Siqueira, Belisa Magalhaes, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

Writing – review & editing: Karan Uppal, Jorge L. Salinas, Wuelton M. Monteiro, Fernando Val, Regina J. Cordy, Ken Liu, Gisely C. Melo, Andre M. Siqueira, Belisa Magalhaes, Mary R. Galinski, Marcus V. G. Lacerda, Dean P. Jones.

References

1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012; 6(9):e1814. Epub 2012/09/13. https://doi.org/10.1371/journal.pntd.0001814 PMID: 22970336; PubMed Central PMCID: PMC3435256.

2. WHO. Malária Report 2016. 2016.

3. Tjitra E, Anstey NM, Sugianto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008; 5(6):e128. Epub 2008/06/20. https://doi.org/10.1371/journal.pmed.0050128 PMID: 18563962; PubMed Central PMCID: PMC2429950.

4. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008; 5(6):e127. Epub 2008/06/20. https://doi.org/10.1371/journal.pmed.0050127 PMID: 18563961; PubMed Central PMCID: PMC2429951.

5. Siqueira AM, Lacerda MV, Magalhaes BM, Mourao MP, Melo GC, Alexandre MA, et al. Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India. BMC
6. Siqueira AM, Mesones-Lapouble O, Marchesini P, Sampaio VS, Brasil P, Tauil PL, et al. Plasmodium vivax Landscape in Brazil: Scenario and Challenges. The American journal of tropical medicine and hygiene. 2016; 95(6 Suppl):87–96. Epub 2016/10/07. https://doi.org/10.4269/ajtmh.16-0204 PMID: 27708190; PubMed Central PMCID: PMC5201227.

7. Kirk K, Saliba KJ. Chloroquine resistance and the pH of the malaria parasite’s digestive vacuole. Drug Resist Updat. 2001; 4(6):335–7. https://doi.org/10.1054/drup.2002.0234 PMID: 12030781.

8. Foley M, Tilley L. Protein trafficking in malaria-infected erythrocytes. International journal for parasitology. 1998; 28(11):1671–80. Epub 1998/12/10. PMID: 9846603.

9. Olafson KN, Ketchum MA, Rimer JD, Vekilov PG. Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine. Proc Natl Acad Sci U S A. 2015; 112(16):4946–51. Epub 2015/04/02. https://doi.org/10.1073/pnas.1501023112 PMID: 27708190; PubMed Central PMCID: PMC4413305.

10. Hempelmann E, Egan TJ. Pigment biocrystallization in Plasmodium falciparum. Trends in parasitology. 2002; 18(1):11. Epub 2002/02/19. PMID: 11850007.

11. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012; 9(2):e1001169. Epub 2012/03/01. https://doi.org/10.1371/journal.pmed.1001169 PMID: 22363311; PubMed Central PMCID: PMC3283556.

12. Sherlach KS, Roepe PD. "Drug resistance associated membrane proteins". Front Physiol. 2014; 5:108. https://doi.org/10.3389/fphys.2014.00108 PMID: 24688472; PubMed Central PMCID: PMC3960488.

13. Chang G. Multidrug resistance ABC transporters. FEBS Lett. 2003; 555(1):102–5. PMID: 14630327.

14. Anderson TJ, Nair S, Qin H, Singlam S, Brockman A, Paiphun L, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrobial Agents Chemotherapy. 2005; 49(6):2180–8. https://doi.org/10.1128/AAC.49.6.2180-2188.2005 PMID: 15917511; PubMed Central PMCID: PMCPMC1140548.

15. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PloS one. 2007; 2(10):e1089. Epub 2007/11/01. https://doi.org/10.1371/journal.pone.0001089 PMID: 17971853; PubMed Central PMCID: PMCPMC3960488.

16. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991; 44(5):547–52. PMID: 1676566.

17. Naing C, Aung K, Win DK, Wah MJ. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010; 104(11):695–705. Epub 2010/09/21. https://doi.org/10.1016/j.trstmh.2010.08.009 PMID: 20850161.

18. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. The American journal of tropical medicine and hygiene. 2001; 65(2):90–3. Epub 2001/08/18. PMID: 11508397.

19. Ruebush TK, 2nd, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. The American journal of tropical medicine and hygiene. 2003; 69 (5):548–52. Epub 2003/12/26. PMID: 14695094.

20. Alecrim MdG, Alecrim W, Macedo V. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Bras Med Trop. 1999; 32(1):67–8. Epub 1999/02/03. PMID: 9927829.

21. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007; 13(7):1125–6. https://doi.org/10.3201/eid1307.061386 PMID: 18214203; PubMed Central PMCID: PMCPMC2878224.

22. Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil LW, et al. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrobial agents and chemotherapy. 2014; 58(1):342–7. Epub 2013/10/30. https://doi.org/10.1128/AAC.02279-12 PMID: 24165179; PubMed Central PMCID: PMC3910749.

23. Siqueira AM, Alencar AC, Mele GC, Magalhaes BL, Machado K, Alencar Filho AC, et al. Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clin Infect Dis. 2017; 64(2):166–74. Epub 2016/12/19. https://doi.org/10.1093/cid/ciw706 PMID: 27988484.
24. Price RN, Nosten F. Single-dose radical cure of Plasmodium vivax: a step closer. Lancet. 2014; 383(9922):1020–1. Epub 2013/12/24. https://doi.org/10.1016/S0140-6736(13)62672-0 PMID: 24360370; PubMed Central PMCID: PMC4627505.

25. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends in parasitology. 2012; 28(11):522–9. Epub 2012/10/10. https://doi.org/10.1016/j.pt.2012.08.005 PMID: 23044287; PubMed Central PMCID: PMC4627502.

26. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhaes BM, Alencar AC, et al. Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PloS one. 2014; 9(8):e105922. Epub 2014/08/27. https://doi.org/10.1371/journal.pone.0105922 PMID: 25157611; PubMed Central PMCID: PMC4144906.

27. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J. 2009; 8:5. Epub 2009/04/04. 1475-2875-8-5 [pii] https://doi.org/10.1186/1475-2875-8-5 PMID: 19341456; PubMed Central PMCID: PMC2682795.

28. Imwong M, Pukrittayakamee S, Pongtavornpiinyo W, Nakeesathit S, Newton P, et al. Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar. Antimicrob Agents Chemother. 2008; 52(7):2657–9. https://doi.org/10.1128/AAC.01459-07 PMID: 18443118; PubMed Central PMCID: PMCPMC2443893.

29. Suwanaruskit R, Chavchich M, Russell B, Jaidee A, Barends M, et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis. 2008; 198(10):1558–64. https://doi.org/10.1086/592451 PMID: 18908339; PubMed Central PMCID: PMCPMC4337975.

30. Vargas-Rodriguez Rdel C, da Silva Bastos M, Menezes MJ, Orjuela-Sanchez P, Ferreira MU. Single-nucleotide polymorphism and copy number variation of the multidrug resistance-1 locus of Plasmodium vivax: local and global patterns. Am J Trop Med Hyg. 2012; 87(5):813–21. https://doi.org/10.4269/ajtmh.2012.12-0094 PMID: 22949516; PubMed Central PMCID: PMCPMC3516255.

31. Shears MJ, MacRae JI, Mollard V, Goodman CD, Sturm A, Orchard LM, et al. Characterization of the Plasmodium falciparum and P. berghei glycerol 3-phosphate acyltransferase involved in FASII fatty acid utilization in the malaria parasite apicoplast. Cell Microbiol. 2017; 19(1). Epub 2016/06/22. https://doi.org/10.1111/cmi.12633 PMID: 27324409.

32. van Schaijk BC, Kumar TR, Vos MW, Richman A, van Gemert GJ, Li T, et al. Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryotic cell. 2014; 13(5):550–9. Epub 2013/12/04. https://doi.org/10.1128/EC.00264-13 PMID: 24297444; PubMed Central PMCID: PMC4060470.

33. Creek DJ, Chua HH, Cobbold SA, Nijagab SL, MacRae JI, Dickerman BK, et al. Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action. Antimicrobial agents and chemotherapy. 2016; 60(11):6635–49. Epub 2016/08/31. https://doi.org/10.1128/AAC.01224-16 PMID: 27572396; PubMed Central PMCID: PMC5075070.

34. Allman EL, Painter HJ, Samra J, Carrasquilla M, Llinas M. Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways. Antimicrobial agents and chemotherapy. 2016; 60(11):6635–49. Epub 2016/08/31. https://doi.org/10.1128/AAC.01224-16 PMID: 27572396; PubMed Central PMCID: PMC5075070.

35. Sakata-Kato T, Wirth DF. A Novel Methodology for Bioenergetic Analysis of Plasmodium falciparum Metabolism Reveals a Glucose-Regulated Metabolic Shift and Enables Mode of Action Analyses of Mitochondrial Inhibitors. ACS Infect Dis. 2016; 2(12):903–16. Epub 2016/10/19. https://doi.org/10.1021/acsinfecdis.6b00101 PMID: 27718558.

36. Decuyper S, Maltha J, Deborggraeve S, Rattray NJ, Issa G, Berenger K, et al. Towards Improving Point-of-Care Diagnosis of Non-malarial Febrile Illness: A Metabolomics Approach. PLoS Negl Trop Dis. 2016; 10(3):e0004480. Epub 2016/03/05. https://doi.org/10.1371/journal.pntd.0004480 PMID: 26943791; PubMed Central PMCID: PMC4778767.

37. Ghosh S, Sengupta A, Sharma S, Sonawat HM. Early prediction of cerebral malaria by 1H NMR based metabolomics. Malari J. 2016; 15:198. Epub 2016/04/14. https://doi.org/10.1186/s12936-016-1256-z PMID: 27067871; PubMed Central PMCID: PMC4628763.

38. Ghosh S, Sengupta A, Sharma S, Sonawat HM. Metabolic perturbations of kidney and spleen in murine cerebral malaria: (1)H NMR-based metabolomics study. PloS one. 2013; 8(9):e73113. Epub 2013/09/17. https://doi.org/10.1371/journal.pone.0073113 PMID: 24039868; PubMed Central PMCID: PMC3765208.

39. Sengupta A, Ghosh S, Das BK, Panda A, Tripathy R, Pied S, et al. Host metabolic responses to Plasmodium falciparum infections evaluated by 1H NMR metabolomics. Mol Biosyst. 2016; 12(11):3324–32. Epub 2016/10/19. https://doi.org/10.1039/c6mb00362a PMID: 2754488.
Metabolomics of *Plasmodium vivax* chloroquine resistance

40. Olszewski KL, Morrissey JM, Wilinski D, Burns JM, Vaidya AB, Rabinowitz JD, et al. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell host & microbe. 2009; 5(2):191–9. Epub 2009/02/17. https://doi.org/10.1016/j.chom.2009.01.004 PMID: 19218089; PubMed Central PMCID: PMC2737466.

41. Hanada K, Palacpac NM, Magistrado PA, Kurokawa K, Rai G, Sakata D, et al. Plasmodium falciparum phospholipase C hydrolyzing sphingomyelin and lysocholinephospholipids is a possible target for malaria chemotherapy. The Journal of experimental medicine. 2002; 195(1):23–34. Epub 2002/01/10. https://doi.org/10.1084/jem.20010724 PMID: 11781362; PubMed Central PMCID: PMC2196011.

42. Jones DP. Sequencing the exposome: A call to action. Toxicol Rep. 2016; 3:329–45. https://doi.org/10.1016/j.toxrep.2015.11.009 PMID: 26722641; PubMed Central PMCID: PMC4692045.

43. Uppal K, Soltow QA, Strobel FH, Pittard WS, Gemert KM, Yu T, et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC bioinformatics. 2013; 14:15. Epub 2013/01/18. https://doi.org/10.1186/1471-2105-14-15 PMID: 23323971; PubMed Central PMCID: PMC3562220.

44. Uppal K, Walker DI, Liu K, Li S, Go YM, Jones DP. Computational Metabolomics: A Framework for the Million Metabolome. Chem Res Toxicol. 2016; 29(12):1956–75. https://doi.org/10.1021/acs.chemrestox.6b00179 PMID: 27629808.

45. Park YH, Shi YP, Liang B, Medriano CA, Jeon YH, Torres E, et al. High-resolution metabolomics to discover potential parasite-specific biomarkers in a Plasmodium falciparum erythrocyte stage culture system. Malar J. 2015; 14:122. Epub 2015/04/19. https://doi.org/10.1186/s12936-015-0651-1 PMID: 25989340; PubMed Central PMCID: PMC4377044.

46. Salinas JL, Kassinger JC, Jones DP, Galinski MR. Metabolomics in the fight against malaria. Memorias do Instituto Oswaldo Cruz. 2014; 109(5):589–97. Epub 2014/09/04. https://doi.org/10.1590/0074-0276140043 PMID: 25185081; PubMed Central PMCID: PMC4476562.

47. Baird JK. Chloroquine resistance in *Plasmodium vivax*. Antimicrob Agents Chemother. 2004; 48(11):4075–83. https://doi.org/10.1128/AAC.48.11.4075-4083.2004 PMID: 15504824; PubMed Central PMCID: PMC4377044.

48. Md S. Guia de Vigilância Epidemiológica. 2009.

49. Snounou G, Vriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, et al. Highly sensitive detection of *Plasmodium vivax* infection in patients treated with chloroquine: evidence for chloroquine resistance. The Journal of experimental medicine. 2002; 195(1):23–34. Epub 2002/01/10. https://doi.org/10.1084/jem.20010724 PMID: 11781362; PubMed Central PMCID: PMC2196011.

50. Roede JR, Uppal K, Tran V, Tran Y, Walker D, et al. Serum metabolomics of slow vs. rapid motor progression Parkinson’s disease: a pilot study. PloS one. 2013; 8(10):e77629. https://doi.org/10.1371/journal.pone.0077629 PMID: 24167579; PubMed Central PMCID: PMC3805572.

51. Accardi CJ, Walker DI, Uppal K, Quyyumi AA, Rohrbeck P, Pennell KD, et al. High-Resolution Metabolomics data. BMC bioinformatics. 2013; 14:15. Epub 2013/01/18. https://doi.org/10.1186/1471-2105-14-15 PMID: 23323971; PubMed Central PMCID: PMC3562220.

52. Go YM, Walker DI, Liang Y, Uppal K, Soltow QA, Tran V, et al. Reference Standardization for Mass Spectrometry and High-resolution Metabolomics Applications to Exposome Research. Toxicol Sci. 2015; 148(2):531–43. https://doi.org/10.1093/toxsci/kfv198 PMID: 26358001; PubMed Central PMCID: PMC4675836.

53. Yu T, Park Y, Johnson JM, Jones DP. apLCMS—adaptive processing of high-resolution LC/MS data. Bioinformatics. 2009; 25(15):1930–6. https://doi.org/10.1093/bioinformatics/btp291 PMID: 19414529; PubMed Central PMCID: PMC2712336.

54. Tautenhahn R, Bottcher C, Neumann S. Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics. 2008; 9:504. https://doi.org/10.1186/1471-2105-9-504 PMID: 19047029; PubMed Central PMCID: PMC2639432.

55. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8(1):118–27. https://doi.org/10.1093/biostatistics/kxj037 PMID: 16632515.

56. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011; 6(6):743–60. https://doi.org/10.1038/nprot.2011.319 PMID: 21637195.

57. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19(2):185–93. Epub 2003/01/23. PMID: 12593298.

58. Koh SM, Klein MS, Hochrein J, Oefner PJ, Spang R, Gronwald W. State-of-the art data normalization methods improve NMR-based metabolomic analysis. Metabolomics: Official journal of the Metabolomic Society. 2012; 8(Suppl 1):146–60. Epub 2012/05/18. https://doi.org/10.1007/s11306-011-0350-z PMID: 22593726; PubMed Central PMCID: PMC3337420.
59. Benjamini Y HY. Controlling the false discovery rate: a practical and powerful approach in multiple testing. J Roy Statist Soc. 1995; Series B 57.

60. Le Cao KA, Gonzalez I, Dejean S. integrOmics: an R package to unravel relationships between two omics datasets. Bioinformatics. 2009; 25(21):2855–6. doi: 10.1093/bioinformatics/btp515 PMID: 19706745; PubMed Central PMCID: PMC2781751.

61. Simon-Manso Y, Lowenthal MS, Kilpatrick LE, Sampson ML, Telu KH, Rudnick PA, et al. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Analytical chemistry. 2013; 85(24):11725–31. doi: 10.1021/ac402503m PMID: 24147600.

62. Uppal K, Walker DJ, Jones DP. xMSannotator: an R package for network-based annotation of high-resolution metabolomics data. Analytical chemistry. 2016. doi: 10.1021/acs.analchem.6b01214 PMID: 27977167.

63. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, et al. Predicting network activity from high throughput metabolomics. PLoS computational biology. 2013; 9(7):e1003123. Epub 2013/07/19. doi: 10.1371/journal.pcbi.1003123 PMID: 23861661; PubMed Central PMCID: PMCPMC2781751.

64. Simon-Manso Y, Lowenthal MS, Kilpatrick LE, Sampson ML, Telu KH, Rudnick PA, et al. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Analytical chemistry. 2013; 85(24):11725–31. doi: 10.1021/ac402503m PMID: 24147600.

65. Smith CA, O’Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005; 27(6):747–51. PMID: 16404815.

66. Available from: https://www.mzcloud.org/.

67. Fauland A, Kofeler H, Trotzmuller M, Knopf A, Hartler J, Eberl A, et al. A comprehensive method for lipid profiling by liquid chromatography-ion cyclotron resonance mass spectrometry. Journal of lipid research. 2011; 52(12):2314–22. Epub 2011/10/01. doi: 10.1194/jlr.D016550 PMID: 21960706; PubMed Central PMCID: PMC3220297.

68. Go YM, Walker DI, Soltow QA, Uppal K, Wachtman LM, Strobel FH, et al. Metabolome-wide association study of phenylalanine in plasma of common marmosets. Amino Acids. 2015; 47(3):589–601. doi: 10.1007/s00726-014-1893-x PMID: 25526869; PubMed Central PMCID: PMCPMC4329061.

69. Schymanski EL, Jeon J, Guilde R, Fenner K, Ruff M, Singer HP, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. 2014; 48(4):2097–8. doi: 10.1021/es5002105 PMID: 24476540.

70. Lohmann C, Schachmann E, Dandekar T, Villmann C, Becker CM. Developmental profiling by mass spectrometry of phosphocholine containing phospholipids in the rat nervous system reveals temporal-spatial gradients. J Neurochem. 2010; 114(4):1119–34. doi: 10.1111/j.1471-4159.2010.06836.x PMID: 20524697.

71. Uppal K, Soltow QA, Promislow DE, Wachtman LM, Quyyumi AA, Jones DP. MetabNet: An R Package for Metabolic Association Analysis of High-Resolution Metabolomics Data. Front Bioeng Biotechnol. 2015; 3:87. doi: 10.3389/fbioe.2015.00087 PMID: 26125020; PubMed Central PMCID: PMC4464066.

72. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. The Journal of infectious diseases. 2001; 183(11):1653–61. Epub 2001/05/09. doi: 10.1086/320707 PMID: 11343215.

73. Sa JM, Nomura T, Neves J, Baird JK, Wellemens TE, del Portillo HA. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol. 2005; 109(4):256–9. doi: 10.1016/j.expara.2004.12.005 PMID: 15755424.

74. Barnadas C, Ratsimbosa A, Tichit M, Boucher C, Jachevitra M, Picot S, et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother. 2008; 52(12):4233–40. Epub 2008/09/24. AAC.00578-08 [pii] doi: 10.1128/AAC.00578-08 PMID: 18809933; PubMed Central PMCID: PMC2592859.

75. Orjuela-Sanchez P, de Santana Filho FS, Machado-Lima A, Chahu N, Costa MR, Alecrim MG, et al. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region. Antimicrob Agents Chemother. 2009; 53(8):3561–4. Epub 2009/05/20. AAC.00004-09 [pii] doi: 10.1128/AAC.00004-09 PMID: 19451296; PubMed Central PMCID: PMC2715622.
76. Chehuan YF, Costa MR, Costa JS, Alecrim MG, Nogueira F, Silveira H, et al. In vitro chloroquine resistance for Plasmodium vivax isolates from the Western Brazilian Amazon. Malar J. 2013; 12:226. Epub 2013/07/04. https://doi.org/10.1186/1475-2875-12-226 PMID: 23819884; PubMed Central PMCID: PMC3704965.

77. Pava Z, Handayani I, Wirjanata G, To S, Trianty L, Novyanti R, et al. Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrob Agents and Chemotherapy. 2015; 60(1):361–7. Epub 2015/11/04. https://doi.org/10.1128/AAC.02207-15 PMID: 26525783; PubMed Central PMCID: PMC4704153.

78. AH S. Malaria and Nutrition. In: Bloem RDSMW, editor. Nutrition and Health: Nutrition and Health in Developing Countries: Humana Press; 2008. p. 229–74.

79. Bingeman TS, Perlman DH, Storey DG, Lewis IA. Digeomtics: an emerging strategy for comprehensive analysis of protein catabolism. Current opinion in biotechnology. 2016; 43:134–40. Epub 2016/12/28. https://doi.org/10.1016/j.copbio.2016.11.004 PMID: 28025112.

80. Orjih AU, Fitch CD. Hemozoin production by Plasmodium falciparum: variation with strain and exposure to chloroquine. Biochimica et biophysica acta. 1993; 1157(3):270–4. Epub 1993/07/11. PMID: 8323956.

81. Wood PA, Eaton JW. Hemoglobin catabolism and host-parasite heme balance in chloroquine-sensitive and chloroquine-resistant Plasmodium berghei infections. The American journal of tropical medicine and hygiene. 1993; 48(4):465–72. Epub 1993/04/01. PMID: 8480854.

82. Lin JW, Spaccapelo R, Schwarz E, Sajid M, Annoura T, Deroost K, et al. Replication of Plasmodium in reticulocytes can occur without hemozoin formation, resulting in chloroquine resistance. The Journal of experimental medicine. 2015; 212(6):893–903. Epub 2015/05/06. https://doi.org/10.1084/jem.20141731 PMID: 25941254; PubMed Central PMCID: PMC4451122.

83. Sullivan DJ Jr., Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A. 1996; 93(21):11865–70. Epub 1996/04/01. PMID: 8876229; PubMed Central PMCID: PMC38150.

84. Lynn A, Chandra S, Malhotra P, Chauhan VS. Heme binding and polymerization by Plasmodium falciparum histidine rich protein II: influence of pH on activity and conformation. FEBS letters. 1999; 459(2):267–71. Epub 1999/10/13. PMID: 10518033.

85. Choi CY, Cerda JF, Chu HA, Babcock GT, Marletta MA. Spectroscopic characterization of the heme-binding sites in Plasmodium falciparum histidine-rich protein 2. Biochemistry. 1999; 38(51):16916–24. Epub 1999/12/22. PMID: 10606526.

86. Bendrat K, Berger BJ, Cerami A. Haem polymerization in malaria. Nature. 1995; 378(6553):138–9. Epub 1995/11/09. https://doi.org/10.1038/378138a0 PMID: 7477315.

87. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998; 55(6):727–36. Epub 1998/05/20. S0006-2952(97)00510-8 [pii]. PMID: 9586944.

88. Dechamps S, Shastri S, Wengelnik K, Vial HJ. Glycerophospholipid acquisition in Plasmodium—a puzzling assembly of biosynthetic pathways. International journal for parasitology. 2010; 40(12):1347–65. Epub 2010/07/06. https://doi.org/10.1016/j.ijpara.2010.05.008 PMID: 20600072.

89. Zidovetzki R, Sherman IW, Cardenas M, Borchardt DB. Chloroquine stabilization of phospholipid membranes against diacylglycerol-induced perturbation. Biochemical pharmacology. 1993; 45(1):183–9. Epub 1993/01/07. PMID: 8424811.

90. Nosal R, Jancinova V, Petrikova M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res. 1995; 77(6):531–42. Epub 1995/03/15. https://doi.org/10.1016/0049-3848(95)00028-3 PMID: 7624839.

91. Gerold P, Schwarz RT. Biosynthesis of glycosphingolipids de-novo by the human malaria parasite Plasmodium falciparum. Molecular and biochemical parasitology. 2001; 112(1):29–37. Epub 2001/02/13. PMID: 11166384.

92. Couto AS, Caffaro C, Uhrig ML, Kimura E, Peres VJ, Merino EF, et al. Glycosphingolipids in Plasmodium falciparum. Presence of an active glucosylceramide synthase. European journal of biochemistry. 2004; 271(11):2204–14. Epub 2004/05/22. https://doi.org/10.1111/j.1432-1033.2004.04150.x PMID: 15153110.

93. Hempelmann E, Motta C, Hughes R, Ward SA, Bray PG. Plasmodium falciparum: sacrificing membrane to grow crystals? Trends in parasitology. 2003; 19(1):23–6. Epub 2002/12/19. PMID: 12488222.

94. Huy NT, Shima Y, Maeda A, Men TT, Hirayama K, Hirase A, et al. Phospholipid membrane-mediated hemozoin formation: the effects of physical properties and evidence of membrane surrounding
110. Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003; 26(8):631–7. Epub 2003/09/12. PMID: 12967198.

111. Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. Journal of immunology. 2010; 184(8):4062–8. [https://doi.org/10.4049/jimmunol.0903002](https://doi.org/10.4049/jimmunol.0903002) PMID: 20368286; PubMed Central PMCID: PMCPMC4077461.

112. Wolday D, Kibreab T, Bukynya D, Hodes R. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1995; 89(6):654–6. Epub 1995/11/01. PMID: 8594686.

113. Hess FI, Iannuzzi A, Leafasia J, Cowdrey D, Nothdurft HD, Von Sonnenburg F, et al. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Acta Trop. 1996; 61(4):293–306. Epub 1996/08/01. PMID: 8910654.

114. Hess FI, Nukuro E, Judson L, Rodgers J, Nothdurft HD, Rieckmann KH. Anti-malarial drug resistance, malnutrition and socio-economic status. Tropical medicine & international health: TM & IH. 1997; 2(8):721–8. Epub 1997/08/01. PMID: 9294541.

115. Hamel MJ, Holtz T, Mkandala C, Kaimila N, Chizani N, Bloland P, et al. Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. The American journal of tropical medicine and hygiene. 2005; 73(3):609–15. Epub 2005/09/21. PMID: 16172491.